ARS Pharmaceuticals (SPRY) Change in Receivables (2024 - 2026)
ARS Pharmaceuticals (SPRY) posted Change in Receivables of $839000.0 for Q1 2026, up 107.51% sequentially from -$11.2 million in Q4 2025, and down 25.62% YoY from $1.1 million in Q1 2025.
ARS Pharmaceuticals (SPRY) Change in Receivables (2024 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Change in Receivables for 3 years, with the latest figure at $839000.0 in Q1 2026.
- Quarterly Change in Receivables fell 25.62% year-over-year to $839000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.9 million (up 81.83% YoY) and the FY2025 annual result came in at $17.2 million, up 110.46% from the prior year.
- Change in Receivables climbed to $839000.0 in Q1 2026 per SPRY's latest filing, from -$11.2 million in the prior quarter.
- Over five years, Change in Receivables peaked at $14.0 million in Q3 2025 and troughed at -$11.2 million in Q4 2025.
- A 3-year average of $3.7 million and a median of $1.1 million in 2025 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 1712.03% in 2025, down 251.0% in 2025.
- Over 3 years, Change in Receivables stood at $7.4 million in 2024, then slumped by 251.0% to -$11.2 million in 2025, then surged by 107.51% to $839000.0 in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered $839000.0, -$11.2 million, and $14.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | 20.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.63 Mn |
| Jun 30, 2026 | 20.63 Mn |
| Mar 31, 2026 | 839,000.00 |
| Mar 31, 2026 | 839,000.00 |
| Dec 31, 2025 | -11.18 Mn |
| Dec 31, 2025 | -11.18 Mn |
| Sep 30, 2025 | 14.01 Mn |
| Sep 30, 2025 | 14.01 Mn |
| Jun 30, 2025 | 13.25 Mn |
| Jun 30, 2025 | 13.25 Mn |
| Mar 31, 2025 | 1.13 Mn |
| Mar 31, 2025 | 1.13 Mn |
| Dec 31, 2024 | 7.40 Mn |
| Dec 31, 2024 | 7.40 Mn |
| Sep 30, 2024 | 773,000.00 |
| Sep 30, 2024 | 773,000.00 |